Shannon Rourke Devens
Corporate Officer/Principal bei SURFACE ONCOLOGY, INC.
Profil
Shannon Rourke Devens is currently working as the Senior Vice President-Development Operation at Surface Oncology, Inc. Prior to this, Shannon worked as the Senior Director-Clinical Operations at Infinity Pharmaceuticals, Inc. Shannon holds a graduate degree from Northeastern University and an undergraduate degree from the University of Colorado Boulder.
Aktive Positionen von Shannon Rourke Devens
| Unternehmen | Position | Beginn |
|---|---|---|
| SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 15.12.2021 |
Ehemalige bekannte Positionen von Shannon Rourke Devens
| Unternehmen | Position | Ende |
|---|---|---|
| INFINITY PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Shannon Rourke Devens
| Northeastern University | Graduate Degree |
| University of Colorado Boulder | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| INFINITY PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Surface Oncology, Inc.
 Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |
